ERBB2 emerges as a new target for colorectal cancer.

ABSTRACT: ERBB2 mutations and amplifications are present in 7% of colorectal cancers. The presence of these alterations may be a marker of resistance to anti-EGFR therapy and, more importantly, could help identify patients who would benefit from ERBB2-directed therapy.

SUBMITTER: Pectasides E 

PROVIDER: S-EPMC4527096 | biostudies-literature | 2015 Aug

REPOSITORIES: biostudies-literature